CNPY2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CNPY2. The page also collects GeneMedi's different modalities and formats products for CNPY2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CNPY2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Secreted Protein/Potential Cytokines.

Predicted to be active in endoplasmic reticulum. [provided by Alliance of Genome Resources, Apr 2022]

Pre-made anti-CNPY2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CNPY2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CNPY2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Recombinant multi-species CNPY2/ HP10390/ MSAP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CNPY2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse canopy 2 homolog (zebrafish) (CNPY2) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Canopy homolog 2 (CNPY2) is an endoplasmic reticulum (ER) luminal protein and belongs to CNPY family. CNPY2? enhance proliferation, migration and tissue revascularization of human smooth muscle cells. CNPY2 inhibit tumor growth and angiogenesis and enhances cell apoptosis through activating p53. Canopy homolog 2 (CNPY2) is also reported to control the outgrowth of neurites, through positive regulation of their outgrowth in neuroblastoma and pheochromocytoma PC12 cells due to stabilizing the myosin regulatory light chain (MRLC), and has been suggested as a novel modulator of cell motility.

Click to check more Cytokine Products